Cargando…

Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade

With the successful development of immune checkpoint blockade, there remains the continued need to improve efficacy and decrease toxicities. The addition of granulocyte–macrophage colony-stimulating factor (GM-CSF) to ipilimumab has previously demonstrated both an improvement in efficacy and decreas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaoyu, Li, Jingjing, Zheng, Yue, Lee, Sandra J., Zhou, Jun, Giobbie-Hurder, Anita, Butterfield, Lisa H., Dranoff, Glenn, Hodi, F. Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398357/ https://www.ncbi.nlm.nih.gov/pubmed/37262321 http://dx.doi.org/10.1158/2326-6066.CIR-22-0702

Ejemplares similares

EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
por: Tabasum, Saba, et al.
Publicado: (2023)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
por: Buchbinder, Elizabeth I., et al.
Publicado: (2021)

OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker
por: Min, Le, et al.
Publicado: (2019)

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
por: Nishino, Mizuki, et al.
Publicado: (2014)

Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells
por: Katsumoto, Tamiko R., et al.
Publicado: (2005)

ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade
por: Ralser, Damian J., et al.
Publicado: (2023)

The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma
por: Wu, Xinqi, et al.
Publicado: (2012)

Su1188 ABDOMINAL CT SHOULD NOT BE USED TO SCREEN FOR IMMUNE CHECKPOINT INHIBITOR COLITIS
por: Braschi-Amirfarzan, Marta, et al.
Publicado: (2020)

Role of Granulocyte-Macrophage Colony-Stimulating Factor Production by T Cells during Mycobacterium tuberculosis Infection
por: Rothchild, Alissa C., et al.
Publicado: (2017)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
por: Wu, Xinqi, et al.
Publicado: (2018)

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
por: Elias, Rawad, et al.
Publicado: (2018)

Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities
por: Mehta, Puja, et al.
Publicado: (2020)

Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma
por: Zhou, Jun, et al.
Publicado: (2011)

Granulocyte colony-stimulating factor blockade enables dexamethasone to inhibit lipopolysaccharide-induced murine lung neutrophils
por: Banuelos, Jesus, et al.
Publicado: (2017)

Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis
por: Bo, Lulong, et al.
Publicado: (2011)

Pilot Study of Delayed ICOS/ICOS-L Blockade With αCD40 to Modulate Pathogenic Alloimmunity in a Primate Cardiac Allograft Model
por: O’Neill, Natalie A., et al.
Publicado: (2018)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
por: Ott, Patrick A, et al.
Publicado: (2021)

Thrombin Stimulates Synthesis of Macrophage Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulating Factor by Human Proximal Tubular Epithelial Cells in Culture
por: Shimaya, Yuko, et al.
Publicado: (2012)

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
por: Koyama, Shohei, et al.
Publicado: (2016)

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
por: Fan, Xiaozhou, et al.
Publicado: (2014)

ICO investors
por: Fahlenbrach, Rüdiger, et al.
Publicado: (2020)

Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)

Granulocyte-macrophage colony-stimulating factor: an immunotarget for sepsis and COVID-19
por: Mu, Xiuying, et al.
Publicado: (2021)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

Immunostimulation using granulocyte- and granulocyte-macrophage colony stimulating factor in patients with severe sepsis and septic shock
por: Schefold, Joerg C
Publicado: (2011)

Transcriptional mechanisms underlying sensitization of peripheral sensory neurons by Granulocyte-/Granulocyte-macrophage colony stimulating factors
por: Bali, Kiran Kumar, et al.
Publicado: (2013)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

Granulocyte Colony Stimulating Factor Expression in Breast Cancer and Its Association with Carbonic Anhydrase IX and Immune Checkpoints
por: Chafe, Shawn C., et al.
Publicado: (2021)

Enhancement of Cytosine Arabinoside Cytotoxicity by Granulocyte/Macrophage Colony‐stimulating Factor and Granulocyte Colony‐stimulating Factor in a Human Myeloblastic Leukemia Cell Line
por: Takauji, Rumiko, et al.
Publicado: (1993)

Orthogonal quantification of soluble inducible T-cell costimulator (ICOS) in healthy and diseased human serum
por: McKinski, Kevin, et al.
Publicado: (2022)

Granulocyte, granulocyte–macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells
por: Pei, X-H, et al.
Publicado: (1999)

Granulocyte Colony-Stimulating Factor in Amniotic Fluid
por: Raynor, B. Denise, et al.
Publicado: (1995)

The importance of the granulocyte-colony stimulating factor in oncology
por: CETEAN, SÎNZIANA, et al.
Publicado: (2015)

Granulocyte Colony-stimulating Factor-associated Aortitis
por: Nishioka, Hiroaki, et al.
Publicado: (2023)

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
por: Ibrahim, Nageatte, et al.
Publicado: (2016)

Colloque ICO '89
por: Moulin, B, et al.
Publicado: (1989)

The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy
por: Solinas, Cinzia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b4d4g5uto6m58de4i32ee43ukl